XTL Biopharmaceuticals adjourns shareholder meeting for quorum

XTL Biopharmaceuticals Ltd. reports that its Extraordinary General Meeting of Shareholders, originally convened on June 22, 2026, was adjourned for one week because not enough shareholders were present to meet the required quorum.

Rhea-AI Filing Summary

XTL Biopharmaceuticals Ltd. reports that its Extraordinary General Meeting of Shareholders, originally convened on June 22, 2026, was adjourned for one week because not enough shareholders were present to meet the required quorum. The meeting is now scheduled to reconvene on June 29, 2026 at 4:00 p.m. Israel time at the offices of the Company’s attorneys in Tel Aviv.

Key Terms

Form 6-K, Foreign Private Issuer, Extraordinary General Meeting, quorum

4 terms

Form 6-K regulatory

"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Foreign Private Issuer regulatory

"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Extraordinary General Meeting financial

"On June 22, 2026, XTL Biopharmaceuticals Ltd. convened an Extraordinary General Meeting of Shareholders"

quorum financial

"the Extraordinary General Meeting was adjourned for one week ... due to lack of quorum"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did XTLB disclose in this June 2026 Form 6-K?

XTL Biopharmaceuticals disclosed that its Extraordinary General Meeting of Shareholders on June 22, 2026 was adjourned due to lack of quorum. The company set a new date and time for the reconvened meeting at its attorneys’ offices in Tel Aviv.

Why was XTL Biopharmaceuticals’ Extraordinary General Meeting adjourned?

The Extraordinary General Meeting was adjourned because a quorum was not present, meaning too few shareholders attended or were represented. Without quorum, the company could not conduct official business or vote on the matters scheduled for that meeting.

When will XTLB’s Extraordinary General Meeting be reconvened?

The Extraordinary General Meeting will be reconvened on Monday, June 29, 2026 at 4:00 p.m. Israel time. It will take place at the offices of the company’s attorneys, Amit, Pollak, Matalon & Co., in the Ramat Hachayal area of Tel Aviv.

Where will XTL Biopharmaceuticals hold the reconvened Extraordinary General Meeting?

The reconvened meeting will be held at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel. This is the office of the company’s attorneys, Amit, Pollak, Matalon & Co., as stated in the disclosure.

Does this XTLB Form 6-K include any financial or earnings information?

No, this Form 6-K focuses solely on procedural details about the Extraordinary General Meeting. It explains the adjournment for lack of quorum and provides the new meeting date, time, and location, without presenting financial results or earnings data.

Who signed XTL Biopharmaceuticals’ June 2026 Form 6-K?

The Form 6-K was signed on behalf of XTL Biopharmaceuticals Ltd. by Noam Band, the company’s Chief Executive Officer. The signature date is June 22, 2026, matching the originally convened Extraordinary General Meeting date mentioned in the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 07:23 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of June 2026

Commission File Number: 001-36000

XTL Biopharmaceuticals Ltd. 

(Exact name of Registrant as specified in its charter)

26 Ben-Gurion St.

Ramat Gan,

5112001, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

On June 22, 2026, XTL Biopharmaceuticals Ltd. (the “Company”) convened an Extraordinary General Meeting of Shareholders (the “Extraordinary General Meeting”). However, the Extraordinary General Meeting was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Extraordinary General Meeting will be reconvened on Monday, June 29, 2026 at 4:00 p.m., Israel time, at the offices of the Company’s attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	XTL Biopharmaceuticals Ltd.
Date: June 22, 2026	/s/ Noam Band
	Noam Band Chief Executive Officer

2